CIP2A

Protein CIP2A · Q8TCG1 · CIP2A on Sugi Atlas →

0 patent compounds predicted against CIP2A, 0 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours

Clinical trials — most relevant to CIP2A by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
Clinical Evaluation of the Effect of Metformin in Sepsis PHASE3UNKNOWN
Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma PHASE2COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients PHASE2COMPLETED
Phase II Study of Sorafenib + Carboplatin and Docetaxel in First Line Treatment of Stage IIIB/IV NSCLC PHASE2COMPLETED
Targeting Endoplasmic Reticulum Stress in Human Hypertension PHASE1/PHASE2RECRUITING
Investigating Datopotamab Deruxtecan Plus Durvalumab Versus Datopotamab Deruxtecan in Patients With PDL1-negative Metastatic Triple-negative Breast Cancer PHASE2RECRUITING
QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic Melanoma PHASE1/PHASE2COMPLETED
A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL PHASE1/PHASE2RECRUITING
Trial of ABI-007 Administered Weekly in Chemotherapy Naive Patients With Advanced Non-Small Cell Lung Cancer PHASE1/PHASE2COMPLETED
Bioequivalence Study of Tacrolimus in Healthy Volunteers PHASE1COMPLETED
Chinese Herbal Formulation PHY906 and Sorafenib Tosylate in Treating Patients With Advanced Liver Cancer PHASE1COMPLETED
GTI-2040 in Treating Patients With Relapsed, Refractory, or High-Risk Acute Leukemia, High-Grade Myelodysplastic Syndromes, or Refractory or Blastic Phase Chronic Myelogenous Leukemia PHASE1COMPLETED
Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas PHASE1COMPLETED
Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors PHASE1COMPLETED
WEE1 Inhibitor MK-1775, Docetaxel, and Cisplatin Before Surgery in Treating Patients With Borderline Resectable Stage III-IVB Squamous Cell Carcinoma of the Head and Neck PHASE1COMPLETED
PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck PHASE1COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma PHASE1COMPLETED
Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies PHASE1COMPLETED
Quantification of GADD34 Expression in RA nanCOMPLETED
Diagnostic of Chemotherapy Induced Neuropathy in Children nanCOMPLETED
Relationship Between Mitochondrial Dysfunction and Fatique in Cancer Patients Following External Beam Radiation Therapy nanCOMPLETED
Duality of Lipids: the Athlete's Paradox nanCOMPLETED
Extracellular Vesicles and Chemotherapy-Induced Peripheral Neuropathy nanRECRUITING
Predictive Role of New Biomarkers for Hypersensitive Patients to Radiation in Breast Cancer (BIORISE) nanACTIVE_NOT_RECRUITING
Effect of Exercise Training on Protein Expression in Skeletal Muscle Tissue After Exercise in Peripheral Arterial Disease nanCOMPLETED
Effect of Transcutaneous Electrical Nerve Stimulation on CIPN Symptoms nanCOMPLETED
Assessing Functional Impairments in Patients With Chemotherapy-Induced Peripheral Neuropathy nanNOT_YET_RECRUITING
Proteomics to Identify Prognostic Markers After CPR and to Estimate Neurological Outcome nanCOMPLETED
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease nanUNKNOWN
Measuring Protein Turnover in Humans Across the Lifespan by Metabolic Labeling With Deuterium Oxide nanRECRUITING

Related proteins — ESM-2 sequence neighbours (a CIP2A binder may also engage these)

ProteinNameSimilarity
Q8BWY9 1.000 Q8BWY9 →
Q5XK92 1.000 Q5XK92 →
Q5ZMJ7 1.000 Q5ZMJ7 →
Q640K1 0.991 Q640K1 →
Q14D04 0.991 Q14D04 →
Q5ZL12 0.991 Q5ZL12 →
Q8H0T4 0.990 Q8H0T4 →
Q6PR54 0.990 Q6PR54 →
Q5PQS3 0.990 Q5PQS3 →
Q7Z3E5 0.990 Q7Z3E5 →
Q19317 0.989 Q19317 →
Q7Z4Q2 0.989 Q7Z4Q2 →
Q8BQM4 0.989 Q8BQM4 →
F6WXT2 0.989 F6WXT2 →
Q5XG71 0.989 Q5XG71 →
Q9Y3R5 0.988 Q9Y3R5 →
A1A535 0.988 A1A535 →
Q5JWR5 0.988 Q5JWR5 →
Q3URQ0 0.988 Q3URQ0 →
Q6NRC9 0.988 Q6NRC9 →
F1QN74 0.988 F1QN74 →
Q8BZM1 0.988 Q8BZM1 →
Q5R629 0.988 Q5R629 →
Q99P25 0.988 Q99P25 →
Q4V9P9 0.987 Q4V9P9 →
Q8WUM0 0.987 Q8WUM0 →
Q2KI89 0.987 Q2KI89 →
Q6GPP1 0.987 Q6GPP1 →
Q9VT41 0.987 Q9VT41 →
Q2TAW0 0.987 Q2TAW0 →